A Case of Hepatitis B Virus Reactivation in a HBsAg-Negative and Anti-HBs-Positive Patient with Diffuse Large B-Cell Lymphoma after Rituximab plus CHOP Chemotherapy
Soonchunhyang Medical Science
; : 168-171, 2014.
Article
en Ko
| WPRIM
| ID: wpr-95062
Biblioteca responsable:
WPRO
ABSTRACT
The reactivation of hepatitis B virus (HBV) is well known complication among lymphoma patient related with chemotherapy. Rituximab is monoclonal antibody that targets B-lymphocytes for treatment of lymphoma and it increases reactivation of HBV. Although most of reactivation occurs in HBV carrier, it can also rarely occur when hepatitis B surface antigen (HBsAg) is negative. Furthermore it is less frequently reported in lymphoma patient when HBV serology shows HBsAg is negative and anti-HBs is positive. We report a case of HBV reactivation following 6 cycle of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy for diffuse large B-cell lymphoma in HBsAg negative/anti-HBs positive 58-year-old male, with a review of the literature.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Vincristina
/
Linfocitos B
/
Doxorrubicina
/
Virus de la Hepatitis B
/
Linfoma de Células B
/
Quimioterapia
/
Rituximab
/
Antígenos de Superficie de la Hepatitis B
/
Linfoma
Límite:
Humans
/
Male
Idioma:
Ko
Revista:
Soonchunhyang Medical Science
Año:
2014
Tipo del documento:
Article